Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Economic information and modeling reportBudget impact modelResults

Base case

1 evidence topic · 2 sources

Budget impact model of tovecimig: base-case results

No evidence found.

Base-case results of United States cost-effectiveness analyses in advanced biliary tract cancer

“ICER was US $381,864/QALY from the US payer perspective and US $367,609/QALY from the Chinese payer perspective.” (opens the source at this quote in a new tab)

“PPPM all-cause costs increased across treatment lines: 1L US $19,589, 2L US $22,617, and 3L US $33,534” (opens the source at this quote in a new tab)

“Mean cost per patient-month was US $7743 (medical services US $6685; drug costs US $1058); median OS was 5.3 months” (opens the source at this quote in a new tab)

“In the US, this treatment was not cost-effective, resulting in an improvement in effectiveness of 0.144 QALYs and an increase in overall cost of $141,000 (ICER of $976,925).” (opens the source at this quote in a new tab)